



Patient ID SA00152321	Patient Name ATLAS REPORT, BALLM ABNORMAL	Birth Date 1980-01-01	Sex M	Age 42
Order Number SA00152321	Client Order Number SA00152321	Ordering Physician CLIENT, CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 02 May 2022 06:45		

B-ALL Monitoring, MRD Detection, V

Final Diagnosis

MCR

Peripheral blood, flow cytometric immunophenotyping:

An abnormal immature B-cell population is detected (MRD=1.26%).

Comment: Minimal residual disease (MRD) is intended to detect small residual populations of B-lymphoblastic leukemia/lymphoma (B-ALL) cells following chemo/immunotherapy or bone marrow transplantation. The sensitivity of this MRD test is 0.002%. Previous therapy targeting cell surface antigen(s) can interfere with this assay's performance. Correlation with clinical features and other laboratory findings is necessary. Contact the signing pathologist at 1-800-533-1710 if there are questions about this analysis.

Reviewed by: SHANDA VOELTZ

Special Studies

MCR

Results:

Blasts: Present Express: CD10 (bright), CD19, CD20 (partial), CD22, CD34 (bright), CD38, CD58. Do not express: CD24, CD45, CD66c. B-ALL MRD analysis: 1.26%

Quality assessment: Specimen received within validated guidelines.

Microscopic Description

1 MCR

A submitted Wright-Giemsa slide and a Wright-Giemsa-stained slide prepared from the flow cytometry specimen are examined.

BALLM Result

MCR

Performed

Received: 02 May 2022 11:27

Reported: 02 May 2022 11:37

Laboratory Notes

- 1 This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292